Regeneron Pharmaceuticals (REGN) Financial Statistics

Biotech

Regeneron Pharmaceuticals (REGN) reported revenue of $14.9B and net income of $4.4B (TTM to Mar 2026, SEC filings). By revenue it ranks #1 of 3 biotech companies covered on autario.

Key metrics at a glance

Revenue

$14.9B

TTM to Mar 2026

Net Income

$4.4B

TTM to Mar 2026

P/E Ratio

16x

as of 2026-07-02

Income Statement

Revenue, operating income, and profitability from SEC filings, trailing-12-month.

Metric	Latest	Period	Source
Revenue	$14.9B	TTM to Mar 2026	SEC EDGAR
Operating Income	$3.6B	TTM to Mar 2026	SEC EDGAR
Net Income	$4.4B	TTM to Mar 2026	SEC EDGAR
Net Margin	29.6%	TTM to Mar 2026	SEC EDGAR

Per Share

Per-share earnings and the share count, split-adjusted to today's basis.

Metric	Latest	Period	Source
Diluted EPS	$40.95	TTM to Mar 2026	SEC EDGAR

Valuation & Market

Share price and market-based valuation, derived from adjusted prices and TTM earnings.

Metric	Latest	Period	Source
Share Price (adjusted)	$654.27	as of 2026-07-02	Market data
P/E Ratio	16x	as of 2026-07-02	SEC EDGAR
Earnings Yield	6.3%	as of 2026-07-02	SEC EDGAR

Biotech peers

Covered same-sector companies on autario, compared on the latest verified figures.

Revenue (TTM) #1 of 3 biotech companies covered

Regeneron Pharmaceuticals (REGN)	$14.9B
Vertex Pharmaceuticals (VRTX)	$12.2B
Insmed Incorporated (INSM)	$819.6M

Sector median: $12.2B

Net Income (TTM) #1 of 3 biotech companies covered

Regeneron Pharmaceuticals (REGN)	$4.4B
Vertex Pharmaceuticals (VRTX)	$4.3B
Insmed Incorporated (INSM)	-$1.2B

Sector median: $4.3B

Use this data programmatically

# Regeneron Pharmaceuticals datasets (JSON, no signup)
curl "https://autario.com/api/v1/public/markets/REGN/datasets"

# Company snapshot (MCP, for LLMs like Claude or ChatGPT)
get_company_snapshot("REGN")

Financial data from SEC EDGAR filings and split-adjusted market prices, aggregated and verified on autario.com. Each value links to its source dataset. Open this profile on autario.com.